LncRNA HClnc1 facilitates hepatocellular carcinoma progression by regulating PKM2 signaling and indicates poor survival outcome after hepatectomy
Cancer Medicine · 2023
DOI: 10.1002/cam4.6117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Qian Zhu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Zhongda Hospital, Southeast University, School of Medicine, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, MicroRNAs, RNA, Long Noncoding. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aim
Long noncoding RNAs (lncRNAs) are key mediators with a wide range of pathophysiological functions, but their role in human hepatocellular carcinoma (HCC) is still unclear.
Methods
An unbiased microarray study evaluated a novel lncRNA, HClnc1, that is linked to the development of HCC. In vitro cell proliferation assays and an in vivo xenotransplanted HCC tumor model were performed to determine its functions, followed by antisense oligo‐coupled mass spectrometry to identify HClnc1‐interacting proteins. To study relevant signaling pathways, in vitro experiments were performed, including chromatin isolation by RNA purification, RNA immunoprecipitation, luciferase, and RNA pull‐down assay.
Results
HClnc1 levels were considerably greater in patients with advanced tumor‐node‐metastatic stages, and it was found to be inversely connected to survival rates. Moreover, the proliferative and invasive potential of the HCC cells was attenuated by HClnc1 RNA knockdown in vitro, while HCC tumor growth and metastasis were found to be reduced in vivo. HClnc1 interacted with pyruvate kinase M2 (PKM2) to prevent its degradation and thus facilitated aerobic glycolysis and PKM2‐STAT3 signaling.
Conclusions
HClnc1 is involved in a novel epigenetic mechanism of HCC tumorigenesis and PKM2 regulation. HClnc1 is not only a more accurate prognostic indicator of HCC but also a potential therapeutic target for HCC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Zhongda Hospital, Southeast University, School of Medicine, Nanjing, Jiangsu, China.
- Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
- First Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
- State Key Laboratory of Bioelectronics, National Demonstration Center for Experimental Biomedical Engineering Education, School of Biological Science and Medical Engineering, Southeast University, Nanjing, Jiangsu, Chin…
- Department of Biochemistry and Molecular Biology, Medical School of Southeast University, Nanjing, Jiangsu, China.
- Department of pathophysiology, Southeast University School of Medicine, Nanjing, Jiangsu, China.
ORCID-Profile: Qian Zhu, Jiahua Zhou
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhu, Q., Lei, Z., Xu, C., Zhang, Z., Yu, Z., Cheng, Z., Xiao, P., Li, S., Yu, W., & Zhou, J. (2023). LncRNA HClnc1 facilitates hepatocellular carcinoma progression by regulating PKM2 signaling and indicates poor survival outcome after hepatectomy. Cancer Medicine. https://doi.org/10.1002/cam4.6117
Vancouver
Zhu Q, Lei Z, Xu C, Zhang Z, Yu Z, Cheng Z, et al. LncRNA HClnc1 facilitates hepatocellular carcinoma progression by regulating PKM2 signaling and indicates poor survival outcome after hepatectomy. Cancer Medicine. 2023. doi:10.1002/cam4.6117
BibTeX
@article{Zhu2023,
author = {Zhu, Qian and Lei, Zhengqing and Xu, Chang and Zhang, Zheng and Yu, Zeqian and Cheng, Zhangjun and Xiao, Pengfeng and Li, Shufeng and Yu, Weiping and Zhou, Jiahua},
title = {LncRNA HClnc1 facilitates hepatocellular carcinoma progression by regulating PKM2 signaling and indicates poor survival outcome after hepatectomy},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6117}
}
EUVIMED